Insmed Incorporated (NASDAQ:INSM) Insider Orlov S. Nicole Schaeffer Sells 91,140 Shares

Insmed Incorporated (NASDAQ:INSM) insider Orlov S. Nicole Schaeffer sold 91,140 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the sale, the insider now owns 97,083 shares of the company’s stock, valued at $7,766,640. The trade was a 48.42 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Insmed Stock Up 0.4 %

NASDAQ INSM traded up $0.29 during trading on Friday, hitting $76.58. The company’s stock had a trading volume of 2,112,773 shares, compared to its average volume of 2,002,774. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.63. The company has a market cap of $13.70 billion, a PE ratio of -13.80 and a beta of 1.12. The business’s 50 day simple moving average is $72.28 and its 200-day simple moving average is $72.97.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. The firm’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same period last year, the business earned ($1.10) earnings per share. On average, equities analysts anticipate that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on INSM shares. JPMorgan Chase & Co. raised their price objective on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, November 22nd. Bank of America raised their price target on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Truist Financial restated a “buy” rating and issued a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Institutional Trading of Insmed

Institutional investors and hedge funds have recently made changes to their positions in the business. V Square Quantitative Management LLC purchased a new stake in shares of Insmed during the third quarter worth approximately $30,000. GAMMA Investing LLC increased its position in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares in the last quarter. Spire Wealth Management purchased a new stake in shares of Insmed during the fourth quarter worth approximately $47,000. Exchange Traded Concepts LLC grew its position in Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Insmed in the 4th quarter valued at about $86,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.